Report
Luis Arredondo
EUR 100.00 For Business Accounts Only

ALMIRALL: PREVIEW RDOS. 4T’22 Y REVISIÓN DE ESTIMACIONES (ANÁLISIS BANCO SABADELL)

Preview Rdos.4T’22 y revisión de estimaciones EBITDA’22-24 -12% y P.O. -11% a 12 euros/acc. COMPRAR
Esperamos Rdos.4T’22 (20/02) marcados por la venta de Motilex en Italia (impacto +5/10 M euros en EBITDA BS(e)) que permitiría a ALM cerrar 2022 en el rango medio de su guidance de “EBITDA entre 190/210 M euros” (-15% vs 2021). 2023 debería ser un año de transición, con márgenes bajo presión y sin catalizadores evidentes, más allá de la aprobación de Lebrikizumab (25% P.O.) en 4T’23 BS(e) cuyo potencial no vemos totalmente recogido en cotización.
Underlying
Almirall SA

Almirall is engaged in the acquisition, manufacture, storage, sale and mediation in the sale of pharmaceutical specialties and products and all manner of raw materials used to prepare pharmaceutical specialties and products. Also, Co. acquires, manufactures, storages, sales and mediates in the sale of cosmetics, chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food-industry use, as well as all manner of utensils, complements and accessories for the chemical, pharmaceutical and clinical industries. In addition, Co. is engaged in the acquisition, sale, lease, subdivision and development of land lots, land and properties of all kinds.

Provider
Sabadell
Sabadell

Analysts
Luis Arredondo

Other Reports on these Companies
Other Reports from Sabadell

ResearchPool Subscriptions

Get the most out of your insights

Get in touch